GlassScriptPhysician profile
Rajendra Prasad
NPI 1427119536
$3,234.42
in general payments reported to CMS, 2019-2025
34 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $90.90 · 2021: $333 · 2022: $794 · 2023: $814 · 2024: $363 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,537.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $512.47 | 2022-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $382.52 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $331.41 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $273.33 | 2019-2025 | Airsupra, Farxiga |
| Neurocrine Biosciences, INC. | $256.75 | 2022-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $191.81 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $170.11 | 2022-2023 | Amyvid, Mounjaro |
| Pfizer INC. | $151.00 | 2019-2024 | |
| Ani Pharmaceuticals, INC. | $116.99 | 2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $102.00 | 2020-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.92 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $50.26 | 2021-2022 | |
| Nevro Corp. | $47.16 | 2022 | |
| Abbvie INC. | $45.42 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $44.84 | 2022-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $43.41 | 2021-2022 | |
| Abbott Laboratories | $42.43 | 2021-2024 | Proclaim |
| Glaxosmithkline, LLC. | $42.10 | 2019-2021 | |
| Tersera Therapeutics LLC | $35.57 | 2023 | Quzyttir |
| Kowa Pharmaceuticals America, INC. | $33.94 | 2024-2025 | Zoryve |
| Sunovion Pharmaceuticals INC. | $33.15 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.94 | 2024 | |
| Esperion Therapeutics, INC. | $29.31 | 2025 | Nexletol |
| Mannkind Corporation | $29.04 | 2025 | |
| Linus Health, INC. | $24.37 | 2022 | |
| Heron Therapeutics, INC. | $23.51 | 2022 | |
| Morphosys, US INC. | $22.10 | 2022 | |
| Eisai INC. | $20.47 | 2021 | |
| Avanir Pharmaceuticals, INC. | $19.41 | 2019 | |
| Evoke Pharma, INC. | $16.59 | 2022 | |
| Horizon Therapeutics Plc | $15.78 | 2019 | |
| Collegium Pharmaceutical, INC. | $15.31 | 2019 | |
| Janssen Biotech, INC. | $14.70 | 2019 | |
| Tactile Systems Technology INC | $14.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajendra Prasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.